1 Result: Longeveron
Longeveron's Lomecel-B shows promise for HLHS patients; Plug Power and Genius Sports report mixed Q1 earnings
May 09th, 2023
Longeveron Inc. (Nasdaq: LGVN) released new long-term follow-up data from its ELPIS I trial, highlighting the potential survival benefit of Lomecel-B for patients with hypoplastic left heart syndrome (HLHS). HLHS is a rare and life-threatening congen. Read more
Load More Content
Want To Find Some News?
Recent Post
-
Earnings Watch: What to Expect from Walt Disney, AppLovin, and DoorDash
August 03rd, 2025Key Earnings on Deck: AMD, Caterpillar, and Amgen to Post Q2 Results
August 03rd, 2025Palantir, Freshpet, and ONEOK Set to Unveil Q2 Earnings
August 03rd, 2025Herbal Works Inc. Announces Three Signature Scents of CBD Bath Bombs
August 01st, 2025
Member Login